Showing results (21-30 of 151) with videos related to
Sort By:
Pageof 16
Urologic Oncology|July 29, 2011
Low-dose diethylstilbestrol for the treatment of advanced prostate cancerJulia Clemons, L Michael Glodé, Dexiang Gao, et al.Urology|May 3, 2011
Pazopanib synergizes with docetaxel in the treatment of bladder cancer cellsYuan Li, Xiaoping Yang, Lih-Jen Su, et al.Clinical Lung Cancer|May 27, 2008
High incidence of lung cancer after non-muscle-invasive transitional cell carcinoma of the bladder: implications for screening trialsKyle E Rusthoven, Thomas W Flaig, David Raben, et al.JACC. Cardiooncology|January 13, 2023
Burden of Cardiovascular Disease in Immune Checkpoint Inhibitor-Treated Patients: Reconciling Adjudicated and Coded OutcomesLavanya Kondapalli, Judith Hsia, Ronni Miller, et al.Bioresearch Open Access|March 22, 2013
miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2Xiaoping Yang, Lynne Bemis, Lih-Jen Su, et al.Oncology (Williston Park, N.Y.)|September 25, 2018
Complications of Androgen Deprivation Therapy in Men With Prostate CancerTejas Patil, Brandon BernardCancer Medicine|December 30, 2015
Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world dataThomas W Flaig, Ravi C Potluri, Yvette Ng, et al.International Journal of Cancer|January 19, 2007
Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cellsThomas W Flaig, Lih-Jen Su, Gail Harrison, et al.Prostate Cancer and Prostatic Diseases|November 19, 2022
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterationsCorbin J Eule, Thomas W Flaig, Katy Wong, et al.Clinical Genitourinary Cancer|September 29, 2012
Thyroid dysfunction in patients treated with sunitinib or sorafenibJulia Clemons, Dexiang Gao, Mary Naam, et al.Pageof 16